Valion Bio (VBIO) Convertible Debt (2025 - 2026)
Valion Bio (VBIO) posted quarterly Convertible Debt of $6.5 million for Q4 2025.
Valion Bio (VBIO) Convertible Debt (2025 - 2026) Analysis & Trends
Valion Bio's Convertible Debt history runs 1 years deep, the most recent figure standing at $6.5 million for Q4 2025.
- In Q4 2025, Convertible Debt changed N/A year-over-year to $6.5 million; the TTM figure through Dec 2025 stood at $6.5 million (changed N/A YoY), while the FY2025 annual figure was $6.5 million, changed N/A from the prior year.
- Convertible Debt for Q4 2025 stood at $6.5 million.
- The five-year high for Convertible Debt was $6.5 million in Q4 2025, with the low at $6.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Valion Bio | 420,133.64 | -1.78 Mn | -45,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.39 Mn |
| Dec 31, 2025 | 6.45 Mn |